Skip to content
Advertisement

This 2018 photo provided by Amylyx shows the company's co-founders Joshua Cohen, left, and Justin Klee in Cambridge, Mass. on Sept. 2, 2022. A closely watched experimental drug for Lou Gehrig’s disease is getting an unusual second look from U.S. regulators on Wednesday, Sept. 7, 2022, amid intense pressure to approve the treatment for patients with the fatal illness. Patients and their families have rallied behind the drug from Amylyx Pharma, launching an aggressive lobbying campaign and enlisting members of Congress to push the Food and Drug Administration to grant approval. (Amylyx via AP, File)

This 2018 photo provided by Amylyx shows the company's co-founders Joshua Cohen, left, and Justin Klee in Cambridge, Mass. on Sept. 2, 2022. A closely watched experimental drug for Lou Gehrig’s disease is getting an unusual second look from U.S. regulators on Wednesday, Sept. 7, 2022, amid intense pressure to approve the treatment for patients with the fatal illness. Patients and their families have rallied behind the drug from Amylyx Pharma, launching an aggressive lobbying campaign and enlisting members of Congress to push the Food and Drug Administration to grant approval. (Amylyx via AP, File)

Featured Photo Galleries

01-Army parade.png

Military parade celebrates Army’s 250th

Cheers and chants rang out Saturday from a crowd of thousands as soldiers manned modern and historic tanks and aircraft for the Army’s 250th anniversary celebration in the District.

20250330 Sabatini-Caps-Sabres 001.jpg

Ovi scores goal 890, Caps lose to Sabres 8-5

Alexander Ovechkin scored goal number 890, but the Washington Capitals fell short, losing to the visiting Buffalo Sabres Sunday afternoon 8-5 at Capital One Arena in Washington D.C., March 30, 2025 (Photos for the Washington Times.)